As shown in Table 2, lncRNA BCAR4 overexpression was correlated with unfavorable OS in patients with osteosarcoma (HR 2.57, 95% CI: 1.53–4.32; P < .001, I2 = 0%), digestive system cancer (HR 2.89, 95% CI: 1.84–4.54; P < .001, I2 = 0%), and other system malignancies (HR 3.00, 95% CI: 1.61–5.60; P < .001, I2 = 0%). This evidence concerns the gene BCAR4 and osteosarcoma.